Literature DB >> 21129165

Clinical predictors of high posttreatment platelet reactivity to clopidogrel in Koreans.

Kyung Woo Park1, Jin Joo Park, Ki-Hyun Jeon, Si-Hyuk Kang, Il-Young Oh, Han-Mo Yang, Hyun-Jai Cho, Hae-Young Lee, Hyun-Jae Kang, Bon-Kwon Koo, Byung-Hee Oh, Young-Bae Park, Hyo-Soo Kim.   

Abstract

INTRODUCTION: High posttreatment platelet reactivity to clopidogrel (HPPR) is associated with major adverse cardiac events. However, the clinical predictors of HPPR in Asians have not been studied previously. AIMS: We sought to determine clinical predictors of HPPR in Koreans.
RESULTS: We measured platelet reactivity with the VerifyNow P2Y12 assay in 1431 consecutive patients undergoing coronary angiography. We used the cut-off value of greater than 275 P2Y12 Reaction Unit (PRU) to define patients with HPPR. The clinical characteristics were compared between patients with HPPR (36.3%) and those without HPPR (63.7%). The mean age (65.4 ± 9.1 vs. 62.2 ± 9.7 years) was higher, hypertension (68.5% vs. 62.0%), diabetes mellitus (35.4% vs. 28.5%), chronic kidney disease (36.3% vs. 22.5%), renal replacement treatment (1.2% vs. 0.2%), and congestive heart failure (1.3% vs. 0.3%) were more common among patients with HPPR, while male gender (72.6% vs. 54.8%) and smoking (19.9% vs. 13.1%) were more common among non-HPPR patients. Mean glomerular filtration rate (63.5 ± 18.6 vs. 69.7 ± 16.1 mL/min/1.73 m(3) ) was lower and C-reactive protein (hs-CRP) (6.6 ± 20.5 mg/L vs. 4.2 ± 12.1 mg/L) level was higher among those with HPPR. Independent predictors of HPPR were female gender (OR 1.90, P≤ 0.001), chronic kidney disease (OR 1.51, 0 = 0.004), diabetes mellitus (OR 1.35, P= 0.024), hs-CRP ≥ 2.0 mg/L (OR 1.31, P= 0.005), and age increase in decades (OR 1.21, P= 0.002), while smoking was negative risk factor (OR 0.63, P= 0.015). The number of risk factors was linearly associated with the risk of HPPR, with most patients having one or two predictors.
CONCLUSION: In Korean population, independent clinical predictors of HPPR included diabetes mellitus, increased age, female gender, chronic kidney disease, and hs-CRP ≥ 2.0 mg/L, while cigarette smoking was associated with better responsiveness. Mean platelet reactivity and HPPR prevalence steadily increased with the number of clinical predictors.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21129165     DOI: 10.1111/j.1755-5922.2010.00249.x

Source DB:  PubMed          Journal:  Cardiovasc Ther        ISSN: 1755-5914            Impact factor:   3.023


  13 in total

1.  The 'Harmonizing Optimal Strategy for Treatment of coronary artery stenosis - sAfety & effectiveneSS of drug-elUting stents & antiplatelet REgimen' (HOST-ASSURE) trial: study protocol for a randomized controlled trial.

Authors:  Kyung Woo Park; Byoung-Eun Park; Si-Hyuck Kang; Jin-Joo Park; Seung-Pyo Lee; Kwang Soo Cha; Jay Young Rhew; Hui-Kyoung Jeon; Eun Seok Shin; Ju Hyeon Oh; Myung-Ho Jeong; Sanghyun Kim; Kyung-Kuk Hwang; Jung-Han Yoon; Sung Yun Lee; Tae-Ho Park; Keon Woong Moon; Hyuck-Moon Kwon; In-Ho Chae; Hyo-Soo Kim
Journal:  Trials       Date:  2012-03-31       Impact factor: 2.279

2.  Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspective.

Authors:  Nicholaos Kakouros; Jeffrey J Rade; Antonios Kourliouros; Jon R Resar
Journal:  Int J Endocrinol       Date:  2011-08-21       Impact factor: 3.257

3.  Antiplatelet effect of clopidogrel can be reduced by calcium-channel blockers.

Authors:  Kwon-Duk Seo; Young Dae Kim; Young-Won Yoon; Jong-Youn Kim; Kyung-Yul Lee
Journal:  Yonsei Med J       Date:  2014-04-01       Impact factor: 2.759

4.  Correlations between High Platelet Reactivity, Extent of Coronary Artery Disease, and Periprocedural Myonecrosis in Patients with Acute Coronary Syndrome.

Authors:  Kyeong Ho Yun; Jum Suk Ko; Jeong Mi Lee; Sang Jae Rhee
Journal:  Chonnam Med J       Date:  2017-05-25

5.  High on-treatment platelet reactivity: risk factors and 5-year outcomes in patients with acute myocardial infarction.

Authors:  Martin Jakl; Robert Sevcik; Ilona Fatorova; Jan M Horacek; Radek Pudil
Journal:  Anatol J Cardiol       Date:  2016-10-05       Impact factor: 1.596

Review 6.  Ethnic Differences in Oral Antithrombotic Therapy.

Authors:  Haechan Cho; Jeehoon Kang; Hyo Soo Kim; Kyung Woo Park
Journal:  Korean Circ J       Date:  2020-08       Impact factor: 3.243

7.  Effectiveness of Platelet Function Analyzer-100 for Laboratory Detection of Anti-Platelet Drug-Induced Platelet Dysfunction.

Authors:  Oh Joo Kweon; Yong Kwan Lim; Bohyun Kim; Mi Kyung Lee; Hye Ryoun Kim
Journal:  Ann Lab Med       Date:  2019-01       Impact factor: 3.464

8.  Genotype- and Phenotype-Directed Personalization of Antiplatelet Treatment in Patients with Non-ST Elevation Acute Coronary Syndromes Undergoing Coronary Stenting.

Authors:  Sung Gyun Ahn; Junghan Yoon; Juwon Kim; Young Uh; Kyung Min Kim; Ji Hyun Lee; Jun-Won Lee; Young Jin Youn; Min-Soo Ahn; Jang-Young Kim; Byung-Su Yoo; Seung-Hwan Lee; Seung-Jea Tahk; Kyung-Hoon Choe
Journal:  Korean Circ J       Date:  2013-08-31       Impact factor: 3.243

9.  Impact of Cytochrome P450 2C19*2 and *3 on Clopidogrel Loading Dose in Saudi Patients with Acute Coronary Syndrome.

Authors:  Hassan Khalaf; Ahmad AbdulRahman Al Meman; Seemab Rasool
Journal:  Drug Metab Lett       Date:  2016

10.  Factors related to on-treatment platelet aggregation assessed by multiple electrode aggregometry in percutaneous coronary intervention patients on clopidogrel and aspirin.

Authors:  Krzysztof Kukula; Mariusz Klopotowski; Joanna Was; Aleksandra Wrobel; Jacek Jamiolkowski; Artur Debski; Pawel Bekta; Zbigniew Chmielak; Adam Witkowski
Journal:  Postepy Kardiol Interwencyjnej       Date:  2017-09-25       Impact factor: 1.426

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.